Trial Profile
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms ABC
- 15 Jul 2022 Status changed from suspended to discontinued.
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 21 Mar 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jul 2022.